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Background: The aim of this Italian multicenter study was to evaluate the
diagnostic performance of a minimally invasive method for the detection of
oral squamous cell carcinoma (OSCC) based on 13-gene DNA methylation
analysis in oral brushing samples.
Methods: Oral brushing specimens were collected in 11 oral medicine centers
across Italy. Twenty brushing specimens were collected by each center, 10 from
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patients with OSCC, and 10 from healthy volunteers. DNA methylation analy-
sis was performed in blindness, and each sample was determined as positive or
negative based on a predefined cutoff value.
Results: DNA amplification failed in 4 of 220 (1.8%) samples. Of the speci-
mens derived from patients with OSCC, 93.6% (103/110) were detected as posi-
tive, and 84.9% (90/106) of the samples from healthy volunteers were negative.
Conclusion: These data confirmed the diagnostic performance of our novel
procedure in a large cohort of brushing specimens collected from 11 different
centers and analyzed in blindness.
KEYWORD S
algorithm, bisulfite sequencing, diagnostic test, oral brushing, oral squamous cell carcinoma,
quantitative DNA methylation analysis
1 | INTRODUCTION
Oral squamous cell carcinoma (OSCC) poses a critical
challenge to public health. Despite the advent of new sur-
gery, radiotherapy, and chemotherapy treatment modali-
ties for the management of patients with OSCC, the
5-year mortality rate remains approximately 60%.1
The prognosis for OSCC of the tongue, the most common
type of OSCC, also remains very poor.2 Furthermore, the
development of a second primary OSCC after surgery is
not uncommon, with frequency ranging between 17%
and 30%.3 This rate is higher than any other type of
tumor and is a leading cause of cancer-related death.4
Although the oral cavity is easily accessible for examina-
tion, only 29% of oral cancers are detected at an early
stage and before metastasis to other sites.5 This is largely
due to the marked biological propensity for local invasion
and the high incidence of cervical lymph node metastasis
at initial diagnosis (40%).6
In current clinical practice, oral cancer screening is
performed solely by oral visual examination, including
inspection and palpation, by general physicians or den-
tists. In cases of suspicious neoplastic or preneoplastic
lesions, patients are referred to oral medicine specialists
or oral/maxillofacial surgeons for a detailed visual oral
examination and further diagnostic biopsy. However,
early detection might be hindered by practitioners' clini-
cal experience and the subtle nature of the lesions, which
may be undetectable by oral examination alone. Thom-
son et al. reported the presence of premalignant lesions
and micro-invasive carcinomas in clinically normal-
appearing oral mucosa.7 The development of a noninva-
sive or minimally invasive diagnostic tool for OSCC
screening and longitudinal monitoring of patients at high
risk of OSCC development, such as patients with oral
potentially malignant disorders (OPMDs) or patients
surgically treated for OSCC, may provide early OSCC
diagnosis and improve the survival of patients
with OSCC.
Currently, no method allowing for screening, early
detection, or monitoring of OSCC in high-risk groups is
commercially available.8 In the past few decades, several
noninvasive diagnostic tools have been proposed, includ-
ing toluidine blue staining, autofluorescence, chemilumi-
nescence, exfoliative cytology, and optical diagnostic
method, such as Raman spectroscopy, elastic scattering,
diffuse reflectance, narrow-band imaging, and fluores-
cence visualization.9,10 However, these methods have sev-
eral limitations, and there is no evidence indicating that
their use could reduce cancer mortality.11 Collection of
samples from oral brushing, mouth rinsing, or saliva for
analysis of OSCC biomarkers has been proposed as an
alternative, noninvasive, or minimally invasive screening
strategy. In recent years, a large number of OSCC bio-
markers have been identified including DNA image cyto-
metry analyzed from quantitative cytology, mRNAs,
microRNAs, proteins, and methylation patterns. For
example, since late 1992, more than 120 biomarkers have
been proposed as diagnostic tools of oral cancer, based on
more than 100 studies.12 Nevertheless, only a few of them
have been validated in clinical samples, and none has
been implemented in clinical practice thus far.
We have recently developed an oral-brushing-based
minimally invasive method to detect oral carcinomas at
an early stage by measuring the DNA methylation levels
of a panel of 13 genes.13 In a single-center study, the
methylation profiles of ZAP70, ITGA4, KIF1A, PARP15,
EPHX3, NTM, LRRTM1, FLI1, MIR193, LINC00599,
MIR296, TERT, and GP1BB were analyzed, and a score
weighting of the best CpGs from all the 13 genes was cal-
culated. In total, 96.6% (n = 28) of OSCC and 100%
(n = 6) of high-grade squamous intraepithelial lesion
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(HGSIL) specimens exceeded the threshold value,
whereas none of the healthy donor samples (n = 65)
exceeded the threshold.13 The clinical relevance of the
method in oral oncology has been confirmed in patients
surgically treated for OSCC; the 13-gene DNA methyla-
tion analysis of samples taken from the regenerative area
after OSCC resection could identify patients at risk of
recurrence during follow-up.14
However, the clinical usefulness of minimally inva-
sive procedures for screening and surveillance in oral
oncology should be comprehensively explored in large
cohort studies and validated in different clinical samples
from different institutions. The aim of this multicenter
study was to assess the sensitivity, specificity, and repro-
ducibility of the 13-gene DNA methylation analysis in
brushing samples from patients with OSCC and healthy
volunteers from 11 different Italian academic oral medi-
cine units.
2 | MATERIALS AND METHODS
2.1 | Study design
This prospective study was conducted from March 2018
to December 2019 using patient samples from 11 oral
medicine units across Italy. The study was coordinated
by the Department of Biomedical and Neuromotor Sci-
ences, Section of Oral Sciences, University of Bologna.
All clinical investigations were conducted according to
the principles of the Declaration of Helsinki. The study
protocol was approved by the ethics committee of Bolo-
gna (study number: 520/2018/Sper/AOUBo; protocol
number: OB-200) and a written informed consent was
obtained from all patients. All information regarding the
human material used in this study was managed using
anonymous numerical codes.
2.2 | Study population and brushing
sampling
Each oral medicine unit collected 20 brushing specimens,
10 from patients with OSCC, and 10 from healthy volun-
teers. Oral brushing sample collection was performed by
clinicians participating in the study using a previously
described method.13,15,16 Briefly, all samples were col-
lected using the same cytobrush (NHMP Co., Ltd., PRC
EC REP, Shanghai International Trading Corporation,
Hamburg, Germany). Exfoliated cells from oral mucosa
were collected after brushing. Each cytobrush sample
was placed in a 2-ml tube containing 500 μl of
DNA/RNA-Shield (Zymo Research, Irvine, CA) for
nucleic acid preservation. Brushing specimens were col-
lected by one operator from each participating center. In
patients with suspected oral neoplastic lesions, the sur-
face of the lesion was gently brushed with rotation and
translation movements. In these patients, oral brushing
was performed before incisional biopsy, and samples
were used in the study only after histological confirma-
tion of OSCC. Clinical information obtained from each
patient with OSCC included age, sex, smoking habits,
clinical appearance, tumor location, and clinical T
(cT) classification. cT classification was based on the oral
examination, imaging data (head and neck CT-scan
and/or MRI), and biopsies of affected areas. Control brus-
hing specimens were collected from healthy volunteers
who presented at each University center during the study
period only for dental care; the healthy volunteers were
matched for age, sex, and smoking habits. Samples from
healthy volunteers who had lesions of any type in the
oral cavity (malignant, potentially malignant, infective,
reactive, or benign) were excluded from the study. In
healthy volunteers the surface of different sites of the oral
mucosa (cheeks, marginal, and dorsal tongue) was gently
brushed with rotation and translational movements.
Samples from each oral medicine unit were submitted to
the coordinating center as masked samples. All brushing
samples were analyzed by the same geneticist (L.M.),
who had no direct access to the codes used for masking
the specimens and who was unaware of the clinical and
provenance information.
2.3 | DNA methylation analysis
DNA methylation analysis was performed as previously
described by Morandi et al.13 Briefly, DNA from exfoli-
ated cells was purified using The MasterPure Complete
DNA Purification Kit (MC85200; Lucigen, Middleton,
WI) and treated with sodium bisulfite using the EZ DNA
Methylation-Lightning Kit (D5031; ZymoResearch,
Irvine, CA) according to the manufacturer's instructions.
Quantitative DNA methylation analysis was performed
by next-generation sequencing for the following genes:
ZAP70, ITGA4, KIF1A, PARP15, EPHX3, NTM, LRRTM1,
FLI1, MIR193, LINC00599, MIR296, TERT, and GP1BB.
Libraries were prepared using the Nextera Index Kit by a
locus-specific bisulfite amplicon approach17 and loaded
onto MiSEQ (15027617; Illumina, San Diego, CA).
FASTQ output files were processed for quality control
(>Q30) and converted into FASTA format in a Galaxy
Project environment.18 The methylation ratio of each
CpG was calculated in parallel by different tools: BSPAT
(http://cbc.case.edu/BSPAT/index.jsp),19 BWAmeth in a
Galaxy Project environment (Europe) followed by the
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MethylDackel tool (https://github.com/dpryan79/
MethylDackel), EPIC-TABSAT,20 and Kismeth.21 The
web tool EasyROC22 was used to calculate the area under
the curve (AUC) for each CpG of the 13 genes and to cre-
ate the heatmap, and ClustVis23 was used for the princi-
pal component analysis (PCA).
In our previous study,13 the best CpGs identified by
receiver operating characteristics (ROC) analysis were
used to generate a choice algorithm based on multiclass
linear discriminant analysis. This allowed us to correctly
identify OSCC with a threshold of 1.0615547 as the best
value for sensitivity and specificity (AUC = 0.981). Using
the same algorithm, in this study, we calculated a specific
score for each sample. Values exceeding the threshold of
1.0615547 were considered positive. The study design is
summarized in the flowchart shown in Figure 1.
2.4 | Statistical analysis
Each sample was analyzed as either a numeric or a
dichotomous variable (positive/negative), according to
the score generated from the algorithm and the cutoff
value calculated previously.13 Kruskal–Wallis analysis
FIGURE 1 Flowchart summarizing the study design [Color figure can be viewed at wileyonlinelibrary.com]
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and Fisher's exact test were used to determine significant
differences between patients with OSCC and healthy vol-
unteers, as well as to evaluate patient variables influenc-
ing the methylation profile in each group (age, sex,
smoking habits for both groups and cT classification,
clinical appearance, and tumor location only for OSCC
group). Kruskal–Wallis analysis was also used to evaluate
differences for each CpG investigated between the
groups. p-values <0.05 were considered statistically sig-
nificant in all analyses.
Using the generated score and ROC analysis, we
evaluated accuracy, sensitivity, and specificity by calcu-
lating the AUC. To assess the diagnostic value of the
13-gene DNA methylation analysis for oral cancer
detection, we calculated the sensitivity, specificity, pos-
itive predictive value (PPV), and negative predictive
value (NPV) with the associated 95% confidence inter-
vals (CIs).
3 | RESULTS
3.1 | Study population
A total of 220 oral brushing specimens were collected
and analyzed from 110 patients with OSCC and
110 healthy volunteers. Patients with OSCC included
55 (50%) females and 55 (50%) males ranging in age from
46 to 97 (median age 68.5 ± 10.3). Fifty-one (46.4%)
patients with OSCC were smokers, whereas the
remaining 59 (53.6%) patients were nonsmokers. Fifty-
nine (53.6%) OSCC lesions were located on tongue
and/or floor of mouth, 18 (16.4%) were located on right
or left cheek or labial mucosa, and 33 (30%) neoplastic
lesions were located on hard palate and/or gingiva.
Twenty-five (22.7%) neoplastic lesions showed a prolifer-
ative aspect, 64 (58.2%) OSCC lesions showed an ulcera-
tive and/or erythroplasic aspect and finally 21 (19.1%)
malignant lesions showed a verrucous and/or a leuko-
plasic aspect.
Finally, 37 (33.6%) neoplastic lesions were cT1,
26 (23.6%) were cT2, 7 (6.4%) were cT3, and 40 (36.4%)
were cT4.
Healthy volunteers included 48 females and 62 males
ranging in age from 32 to 85 (median age 61.5 ± 11.3).
Thirty-seven (33.6%) healthy volunteers were smokers
and 73 (66.4%) were nonsmokers. The patient character-
istics were summarized in Table 1.
DNA amplification was not possible in 4 of the
220 (1.8%) samples; thus, the final brushing sample col-
lection consisted of 216 brushing specimens, including
110 brushing specimens from patients with OSCC and
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3.2 | 13-gene DNA methylation analysis
A mean score of 2.74 ± 1.6 was calculated for brushing
specimens collected from patients with OSCC. Scores for
103 of the 110 specimens (93.6%) exceeded the threshold
value and were considered positive. On the other hand,
brushing specimens from healthy volunteers had a mean
score value of −0.11 ± 1.2. The scores for 16 of the
106 specimens (15.1%) from healthy volunteers exceeded
the threshold value and were considered positive. None
of the healthy volunteers developed OSCC during the
study period. Calculated scores and threshold values are
summarized in Table 2.
TABLE 2 Score samples for each oral medicine unit
Centers
OSCC samples Healthy donors
13-gene DNA methylation analysis 13-gene DNA methylation analysis
Mean score value Positive test Negative test Mean score value Positive test Negative test
Center 1 3.68 ± 1.9 10 0 −0.18 ± 0.9 1 9
Center 2a 1.04 ± 1.7 6 4 0.86 ± 0.3 4 5
Center 3 2.52 ± 1.3 9 1 −0.62 ± 1.4 1 9
Center 4 2.93 ± 1.9 9 1 0.61 ± 0.7 3 7
Center 5 2.87 ± 1.4 10 0 0.09 ± 1.3 2 8
Center 6b 3.13 ± 0.8 10 0 0.18 ± 1.1 1 7
Center 7 3.02 ± 1.2 10 0 −0.67 ± 1.16 1 9
Center 8a 2.42 ± 2.2 10 0 −0.34 ± 1.1 1 8
Center 9 2.89 ± 1.2 9 1 −0.15 ± 0.8 1 9
Center 10 2.6 ± 1.3 10 0 0.26 ± 1.1 1 9
Center 11 3.07 ± 1.4 10 0 −1.16 ± 0.6 0 10
TOT 2.7 ± 1.6 103 7 −0.12 ± 1.2 16 90
Abbreviation: OSCC, oral squamous cell carcinoma.
a13-gene DNA methylation analysis was not possible in one brushing sample collected in the group of healthy donors.
b13-gene DNA methylation analysis was not possible in two brushing samples collected in the group of healthy donors.
FIGURE 2 Box plot showing the scores calculated using the
algorithm showed a significant between-group difference (Kruskal–
Wallis test T = 123.1; p < 0.05). The calculated sample scores
differed significantly between patients with oral squamous cell
carcinoma (OSCC) and healthy volunteers
FIGURE 3 Receiver operating characteristics (ROC) analysis
showing the ability of the score calculated from the algorithm to
discriminate brushing samples acquired from oral squamous cell
carcinoma (OSCC) and healthy volunteers. The area under the
curve (AUC) was 0.937
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The calculated sample scores differed significantly
between patients with OSCC and healthy volunteers, as
determined by Fisher's exact test (Chi 134.6, p < 0.000)
and Kruskal–Wallis analysis (T = 123.1, p < 0.05)
(Figure 2). Moreover, we found a significant difference
between patients with OSCC and healthy volunteers in
the CpGs of the 13 genes used to generate the choice
algorithm (p < 0.05; Kruskal–Wallis test; Figure S1,
Supporting Information).
The diagnostic value of the 13-gene DNA methylation
analysis in oral brushing samples for OSCC detection
was assessed using the cutoff value determined in our
previous study.13 We found that our method provided
sensitivity of 93.6% (CI 87.8–99.5), specificity of 84.9%
(CI 76.2–93.6), PPV of 86.6% (CI 78.7–94.4), NPV of 92.8%
(CI 86.2–99.4), and accuracy of 89.4%. Furthermore, ROC
curve analysis using the calculated sample scores pro-
vided an AUC of 0.937 (Figure 3). ROC analyses were
also performed for each CpG of the 13 genes. The results
of these analyses are summarized in Figure S2 and
Table S1.
The 216 specimens used in this study were classified
into four groups based on the quantitative 13-gene DNA
methylation analysis results: true positive cases (TP:
patients with OSCC detected as positive; n = 103), false
negative cases (FN: patients with OSCC detected as nega-
tive; n = 7), false positive cases (FP: healthy volunteers
detected as positive; n = 16), and true negative cases (TN:
healthy volunteers detected as negative; n = 90). None of
the patient variables analyzed in this study
(cT classification, tumor location, and clinical appearance
for OSCC group and age, sex, and smoking habits for
both groups) had a significant effect on the score calcu-
lated in these four different groups (Table 3). In particu-
lar, the number of 7 FN cases resulted equally distributed
on the basis of cT classification (3cT1, 1 cT2, and 3cT4).
Heatmap clustering provided two main clusters; the right
cluster included 86 TN, all 7 FN, 10 FP, and 10 TP sam-
ples; the left cluster included 93 TP, 4 TN, and 6 FP sam-
ples. The heatmap and ClustVis results are shown in
Figures S3 and S4, respectively.
4 | DISCUSSION
This study is the first multicenter oral oncology study to
investigate the diagnostic value of a minimally invasive
method for early detection of oral cancer based on
genetic and epigenetic analyses. Several studies suggested
the potential use of single biomarkers or a panel of bio-
markers for early detection of OSCC starting from nonin-
vasive or minimally invasive sampling methods.24-30 In














































































































































































































































































































































































































































8 GISSI ET AL.
analysis of DNA methylation status of several genes
starting from saliva or oral brushing specimens as prom-
ising biomarker.31-38 The majority of these authors pro-
posed a study model that included patients with OSCC
and non-OSCC normal controls to explore the diagnostic
value of potentially OSCC biomarker. However so far,
none of these biomarkers has been implemented in clini-
cal practice. In a previous study, we reported the develop-
ment of a novel assay for early detection of OSCC and
HGSIL from oral brushing specimens using bisulfite
next-generation sequencing.13 Using linear discriminant
analysis, we calculated for each sample a score weighted
by the best CpGs of a panel of 13 genes. Combination of
epigenetic profiles of several genes rather than a single
gene as useful source of information in the complex
OSCC landscape is in agreement with emerging publi-
shed literature. Different authors proposed the use a
panel of several genes with an aberrant methylation sta-
tus in OSCC31,34,35,39 rather than a single or few
genes32,36-38 for diagnostic and prognostic purposes. The
ability of our method to discriminate patients with oral
cancer from healthy individuals was very high, with an
AUC of 0.981. Impressively, 28 of 29 OSCC (96.6%) and
6 of 6 HGSIL (100%) specimens exceeded the threshold
value, whereas none of the 65 specimens from healthy
donors exceeded the threshold.
This performance was achieved by a bisulfite NGS
approach, which gives several advantages: a small
amount of DNA obtaining from a minimally or noninva-
sive sampling procedure is necessary for analysis of epi-
genetic alterations, different genes, and their CpGs
usually mapped at the promoter level; quantitative data
are available calculating the number of reads with associ-
ated unconverted C in each CpG position; the pattern of
each epiallele in cis may be defined interpreting its
homogeneous or heterogeneous behavior; as reported
previously by Bock et al. who compared the most promis-
ing assays for measuring DNA methylation in clinical
diagnostics, best performances were obtained using
amplicon bisulfite sequencing with high accuracy and
robustness.40 (Assigning at least 1000–2000 reads per sin-
gle region of interest, up to 96 different specimens can be
loaded per single run using a micro flow-cell Illumina;
moreover, since the library preparation is based on a two-
step PCR approach, the total cost of the assay is very lim-
ited if compared to other library preparation protocols
(see details in Section 2).) In this study, we validated the
sensitivity and specificity of the method in an extensive
collection of 220 brushing specimens collected in 11 oral
medicine units from different parts of Italy. To the best of
our knowledge, this is the first multicenter study demon-
strating the diagnostic value of a minimally invasive
method, which could provide early detection of oral can-
cer based on genetic and epigenetic analyses.
Our data confirmed the feasibility of the newly devel-
oped method. Indeed, in our previous study oral brushing
cell collection was always performed by the same opera-
tor in a single oral medicine center, whereas in this study
11 different operators collected, stored, and mailed in
blindness oral brushing specimens from different oral
medicine centers across Italy. Brushing specimens con-
tained sufficient DNA for quantitative DNA methylation
analysis, except in 4 of 220 samples in which DNA ampli-
fication failed. ROC curve analysis based on the quantita-
tive scores confirmed the high accuracy of the method,
with an AUC of 0.937. In particular, 93.6% (103/110) of
the brushing specimens collected from patients with oral
neoplastic lesions were identified in blindness as positive,
and 84.9% (90/106) of the samples from healthy individ-
uals were identified as negative. No clinical or differences
regarding patient variables (age, sex, and smoking habits)
and tumor variables (cT classification, tumor location,
and clinical appearance) were observed between OSCC
specimens with positive and negative scores. Moreover,
no significant differences in age, sex, or smoking habits
were observed between TN and FP specimens.
While a low number of FPs would minimize unneces-
sary examinations and anxiety, the development of diag-
nostic tests with minimal numbers of FN findings is of
high clinical importance.8 In general, sensitivity and
specificity values of at least 80% are required. It is worth
noting that four of seven false-negative samples were
consecutive specimens acquired from a single center
(center 2). Therefore, the low diagnostic performance of
our method in these particular samples may be due to
incorrect sampling, leading to the acquisition of insuffi-
cient numbers of cancer cells from the lesion. Alterna-
tively, incorrect storage or problems in the mailing
procedure may have occurred, as four FP samples were
also obtained from the same center. Nevertheless, we
cannot exclude the possibility that a small subgroup of
OSCCs may show different methylation patterns. Consid-
ering that this was a multicenter study, with an extensive
number of samples and a wider range of participants, the
sensitivity of the method is extremely promising.
No diagnostic tests have been proven to be cost-
effective for detecting oral lesions in the general popula-
tion thus far,11 as the prevalence of oral cancer in the
general population is low.1 The fact that our method pro-
vides high sensitivity (93.6%) and NPV (92.7%) suggests
its clinical usefulness as a first-line screening tool in oral
cancer detection in the general population, although it
should not be ignored the presence of 16% FP findings
reported herein. A strict follow-up of the latter is ongoing
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to verify if they are really FP cases or if they are at
increasing risk to develop a lesion later on.
To reduce the number of FP cases and to improve the
cost-effectiveness of our procedure, further investigations
will be performed to identify local or systemic variables
in healthy volunteers (i.e., local benign chronic or acute
inflammations, use for systemic drugs) not included in
this study design and responsible of an altered methyla-
tion profile of one or different genes of our 13-gene
panel.
Further investigations will be also performed to eval-
uate the role of our procedure not only in presence of a
suspected neoplastic lesion but also as a surveillance tool
for high-risk OSCC groups of patients (i.e., patients with
potentially malignant disorders and/or patients surgically
treated for OSCC). A study design with brushing cell col-
lection at different moments during the follow-up period
of these patients will evaluate the potential role of our
procedure as an indicator of disease before the appear-
ance of clinical signs of oral cancer.
5 | CONCLUSION
Herein, we reported the first multicenter study investi-
gating the feasibility and diagnostic value of a mini-
mally invasive method for the detection of oral cancer
based on genetic and epigenetic analyses. Our findings
confirmed the high accuracy of the test in an extensive
collection of clinical samples. Although the method
exhibited high sensitivity, the specificity was slightly
lower than expected based on data from our previous
study. These findings suggest that this easy-to-perform
method could be proposed not in replacement of oral
biopsy for definitive diagnosis but as a reliable mea-
sure of oral cancer risk, and should be provided to
high-risk patients by primary health care providers,
dentists, oral medicine specialists, and oral/maxillofa-
cial surgeons.
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